This news release for
Sagicor Financial Company Ltd. ("Sagicor" or the "Company") should
be read in conjunction with the Company's Management's Discussion
& Analysis ("MD&A") and the Consolidated Financial
Statements for the period ended September 30, 2023. These documents
are available on Sagicor's website, at www.sagicor.com, under the
heading "Financials and Filings", and under Sagicor's profile at
www.sedarplus.ca. This news release presents non-IFRS measures used
by Sagicor in evaluating its results and measuring its performance.
These non-IFRS measures are not standardized financial measures,
are not included in the Consolidated Financial Statements, and may
not be comparable to similar financial measures used by other
companies. They include return on shareholders' equity, book value
per share, debt to capital ratio, total capital, revenues,
contractual service margin, Minimum Continuing Capital and
Surplus Requirement ratio, and core earnings. See the
"Non-IFRS Measures" section in this document for relevant
information about such measures.
|
TORONTO and BARBADOS, Nov. 13,
2023 /CNW/ - Sagicor Financial Company Ltd. (TSX:
SFC), a leading financial services provider in the Caribbean and Canada, with a growing presence in the U.S.,
today announced its results for the third quarter ended
September 30, 2023. All figures are
in US$ unless otherwise stated.
Q3 Highlights
- Revenues(1) of $291.2 million
- Insurance revenue of $181.3
million
- Net insurance and investment result of $97.9 million
- Net loss to shareholders of $3.5
million
- Estimated core earnings to shareholders(1) of
$9.0 million
- Total comprehensive loss to shareholders of $11.0 million
- New business CSM(1) of $25.7 million
- Total net CSM(1) of $698.6 million
- Shareholders' equity and net CSM to
shareholders(1) of $1.0
billion
- MCCSR ratio(1) of 259%
- Dividend of US$0.05625 per
common share to be paid during the fourth quarter of 2023
(US$0.225 annualised dividend)
Andre Mousseau, President and
Chief Executive Officer, said:
"We are pleased to have delivered another solid quarter in Q3.
Our estimated core earnings to shareholders(1) of
$9 million were slightly below our
forecasts and included some adverse experience in the quarter. Our
net loss to shareholders of $3.5
million included one-time costs relating to IFRS 17 and our
ivari acquisition, non-cash accounting charges associated with
rising interest rates, and the results of our annual review of our
actuarial assumptions. We believe our year-to-date net income to
shareholders of $47 million through
nine months represents a more accurate approximation of our earning
power of our prior legacy business."
"We are particularly pleased to have been able to close the
acquisition of ivari in the beginning of the fourth quarter. The
immediate debt ratings upgrades validated our improved asset base
and stronger overall financial position. Further, the rise in
interest rates in the third quarter had a positive effect on
ivari's embedded profitability, which will result in a book value
gain at or above the high end of our initial estimates. These
higher interest rates are also making the fundamental economics of
our new business more attractive than they have been in recent
years. We are excited about our growth prospects going forward and
we look forward to filing our business acquisition report, which
will detail our pro-forma financials, in December."
____________________________________
|
1
|
Represents a Non-IFRS
measure. See the Non-IFRS Measures section in this document and in
our MD&A for relevant information about such
measures.
|
Overall Sagicor Group – Quarterly Highlights
In Q3 2023 Sagicor continued momentum in new business production
while navigating rising interest rates and some continued adverse
experience. Each of our segments delivered strong insurance
revenue and new business CSM. Sagicor's Q3 2023 net loss to
shareholders of $3.5 million was
primarily caused by changes in actuarial assumptions as part of
Sagicor's annual review and other one-time charges and expenses.
Sagicor remains well capitalized with an MCCSR
ratio(1) for its insurance businesses of 259% and a
debt to capital ratio(1) of 31.0%.
Sagicor intends to disclose a drivers of earnings analysis and
adopt a non-IFRS core earnings measure in future quarters. Sagicor
believes this will support users' understanding of the underlying
financial performance and the long-term performance and valuation
of the business. We estimate core earnings to
shareholders(1) under the currently proposed
definition for Q3 2023 to be $9.0
million which excludes $12.5
million of adjustments from net loss to shareholders. The
adjustments in the third quarter consist of $2.4 million of market experience gains,
$10.3 million in losses from changes
in actuarial methods and assumptions, $3.8
million in one-time costs from IFRS 17 implementation and
the ivari acquisition, and $3.0
million of other loss adjustments partially offset by
$2.2 million of the tax effects of
the foregoing.
Consolidated Highlights
Profitability (US$
millions)(2)
|
Q3
2023
|
Restated
Q3
2022
|
Change
Y/Y
|
YTD
2023
|
Restated
YTD 2022
|
Change
Y/Y
|
Net income (loss) to
shareholders
|
(3.5)
|
(74.1)
|
95 %
|
46.7
|
(236.3)
|
n.m.(3)
|
Annualized return on
shareholders' equity(1) (%)
|
(3.1 %)
|
n.m.(3)
|
n.m.(3)
|
14.3 %
|
n.m.(3)
|
n.m.(3)
|
New Business
CSM(1)
|
25.7
|
54.3
|
(53 %)
|
102.3
|
147.3
|
(31 %)
|
|
|
|
|
|
|
|
Financial Strength
(US$ millions)
|
Q3
2023
|
Q2
2023
|
Change
Q/Q
|
|
|
|
Shareholders'
equity
|
442.5
|
462.5
|
(4 %)
|
|
|
|
Net CSM to
shareholders(1)
|
558.9
|
573.4
|
(3 %)
|
|
|
|
Shareholders' equity
and net CSM to Shareholders(1)
|
1,001.4
|
1,035.9
|
(3 %)
|
|
|
|
Total net
CSM(1)
|
698.6
|
697.1
|
0 %
|
|
|
|
Book value per
share(1) (US$ per share)
|
$3.12
|
$3.24
|
(4 %)
|
|
|
|
MCCSR
ratio(1)
|
259 %
|
286 %
|
(27 pts)
|
|
|
|
Debt to capital
ratio(1)
|
31.0 %
|
30.4 %
|
0.6 pts
|
|
|
|
|
_____________________________________
|
2
|
Represents a non-IFRS
measure. See the Non-IFRS Measures section in this document and in
our MD&A for relevant information about such
measures.
|
3
|
Prior period amounts
were restated to conform to current period presentation.
|
4
|
Not
meaningful.
|
ivari Update and Outlook
On October 3, 2023, as previously
announced, Sagicor completed the acquisition of ivari. Sagicor's
results for the three- and nine-month periods ending September 30, 2023, do not reflect contributions
from ivari, other than certain transaction costs that have been
expensed or capitalized in connection with the acquisition.
Starting in Q4 2023, Sagicor's consolidated financial results will
include ivari's results as a new operating segment.
Sagicor is commenting on its preliminary guidance and
anticipated pro-forma impacts of the ivari transaction as disclosed
in previous press releases. All IFRS 17 financial information is
unaudited, provided for informational purposes only, and is
pro-forma and forward-looking in nature. It is not necessarily
indicative of what Sagicor's or ivari's results of operations would
have been had Sagicor or ivari reported under IFRS 17 as of
January 1, 2022. The impact accounts
for the acquisition of ivari with a close date of October 3, 2023, and it is expected to have the
following pro-forma impacts:
- Sagicor's current Q3 2023 shareholders' equity of $443 million would increase primarily by the
bargain purchase gain (negative goodwill) created by the purchase
price being lower than ivari's adjusted net assets acquired.
Pro-forma we expect shareholders' equity will be at or above the
high end of our previous guidance of $650 to $725
million;
- Sagicor's current Q3 2023 net CSM to shareholders(1)
is $559 million and pro-forma we
expect net CSM to shareholders will be approximately $1.1 to $1.3
billion;
- Sagicor's current Q3 2023 shareholders' equity and net CSM to
shareholders capital is $1.0 billion
and pro-forma we expect shareholders' equity and net CSM to
shareholders capital will be at or above the high end of the
previous guidance of approximately $1.8 to $2.0
billion;
- Sagicor's standalone 2024 return on shareholders'
equity(1) is expected to be approximately 14 to 16%, and
pro-forma the ivari acquisition is expected to be at the low range
of the previous guidance of 14 to 16%, largely reflecting the
increase in pro-forma shareholders' equity rising more than our
increase in forward earnings;
- Beyond 2024 the pro-forma company will target high single-digit
net CSM to shareholders(1) growth and double-digit net
income to shareholders growth;
- ivari is expected to be accretive on a book value and earnings
basis; and
- The debt to capital (including total net CSM)(1)
ratio of 31.0% as at Q3 3023 is expected to be neutral or better
pro-forma the acquisition.
_____________________________________
|
1
|
Represents a non-IFRS
measure. See the Non-IFRS Measures section in this document and in
our MD&A for relevant information about such
measures.
|
Business Segment Performance
Sagicor has three main reporting operating segments: Sagicor
Life (which includes the southern Caribbean), Sagicor Jamaica (of which the
Company owns 49.1% and which is consolidated by the Company), and
Sagicor Life USA.
Performance (US$
millions)(1)
|
Q3
2023
|
Restated
Q3
2022
|
Change
Y/Y
|
YTD
2023
|
Restated
YTD 2022
|
Change
Y/Y
|
Revenues(2)
|
|
|
|
|
|
|
Sagicor Life
|
108.9
|
95.7
|
14 %
|
326.1
|
278.8
|
17 %
|
Sagicor
Jamaica
|
138.1
|
103.3
|
34 %
|
449.7
|
274.0
|
64 %
|
Sagicor Life
USA
|
52.6
|
(92.8)
|
>100%
|
259.5
|
(399.4)
|
>100%
|
Head
office(8)
|
(8.4)
|
(3.3)
|
(>100%)
|
(12.9)
|
(31.5)
|
59 %
|
Total
|
291.2
|
102.9
|
>100%
|
1,022.4
|
121.9
|
>100%
|
Insurance
Revenue
|
|
|
|
|
|
|
Sagicor Life
|
76.4
|
71.6
|
7 %
|
223.2
|
213.8
|
4 %
|
Sagicor
Jamaica
|
79.7
|
65.1
|
22 %
|
224.6
|
189.3
|
19 %
|
Sagicor Life
USA
|
25.1
|
15.6
|
61 %
|
65.6
|
47.6
|
38 %
|
Head
office(3)
|
-
|
-
|
-
|
-
|
-
|
-
|
Total
|
181.3
|
152.2
|
19 %
|
513.4
|
450.7
|
14 %
|
Net Income / (Loss)
to Shareholders
|
|
|
|
|
|
|
Sagicor Life
|
3.6
|
(10.9)
|
>100%
|
17.4
|
(9.7)
|
>100%
|
Sagicor
Jamaica
|
14.2
|
(12.5)
|
>100%
|
32.3
|
(1.7)
|
>100%
|
Sagicor Life
USA
|
5.1
|
(26.6)
|
>100%
|
64.1
|
(137.4)
|
>100%
|
Head
office(3)
|
(26.4)
|
(24.1)
|
(10 %)
|
(67.1)
|
(87.5)
|
23 %
|
Total
|
(3.5)
|
(74.1)
|
95 %
|
46.7
|
(236.3)
|
>100%
|
New Business
CSM(2)
|
|
|
|
|
|
|
Sagicor Life
|
12.0
|
10.5
|
14 %
|
38.0
|
33.0
|
15 %
|
Sagicor
Jamaica
|
8.3
|
8.5
|
(2 %)
|
24.6
|
24.8
|
(1 %)
|
Sagicor Life
USA
|
5.3
|
35.3
|
(85 %)
|
39.6
|
89.5
|
(56 %)
|
Head
office(3)
|
-
|
-
|
-
|
-
|
-
|
-
|
Total
|
25.7
|
54.3
|
(53 %)
|
102.2
|
147.3
|
(31 %)
|
|
____________________________________
|
1
|
Prior period amounts
were restated to conform to current period presentation.
|
2
|
Represents a non-IFRS
measure. See the Non-IFRS Measures section in this document and in
our MD&A for relevant information about such
measures.
|
3
|
Head office includes
parent company financing costs, administrative expenses, the
interest in Playa Hotels and Resorts, other operating companies,
adjustments, and other.
|
Business Segment - Quarterly
Highlights
Sagicor Life
- Sagicor Life saw growth in insurance revenue that was offset by
an increase in total insurance expenses. General growth in the
insurance portfolio was impacted by higher claims and cost
inflation in the property and casualty and employee benefits
businesses.
- Effect of our annual review of assumptions was a $1.3 million positive contribution to pre-tax net
income to shareholders and a $6.2
million negative contribution to total net CSM.
- Net income to shareholders was $3.6
million, below target due to negative experience.
- Total net CSM(1) was $245.1
million, neutral Q/Q largely due to new business
CSM(1) of $12.0 million
during the quarter offset by negative lapse and persistency
experience.
Sagicor Jamaica
- Sagicor Jamaica had solid production in the long-term life
business as well as strong results in its short-term insurance
businesses, largely as a result of increased premium rates. The
segment continued to benefit from an improved Jamaican
economy.
- Effect of our annual review of assumptions was no change to
pre-tax net income to shareholders and a $30.1 million positive contribution to total net
CSM.
- Sagicor's share of Sagicor Jamaica's net income to shareholders
was $14.2 million.
- Total net CSM(1) was $274.4
million which grew Q/Q due to new business CSM(1)
of $8.3 million and reflected
favorable critical illness experience.
Sagicor Life USA
- Sagicor Life USA's new
business production(1) of $172.1
million was robust in a favorable interest rate environment
for new business.
- Effect of our annual review of assumptions was an $11.6 million negative contribution to pre-tax
net income to shareholders and a $30.0
million negative contribution to total net CSM reflecting
actions taken in reaction to rising interest rates.
- Net income to shareholders, including the effects of assumption
changes, was of $5.1 million.
- Total net CSM(1) was $178.7
million, a decrease Q/Q primarily due to the impact of
actuarial assumptions and management actions which more than offset
robust new business CSM.
Head Office, Other, and Adjustments
- Net loss to shareholders of $26.4
million.
Dividends
On November 9, 2023, the Board of Directors of Sagicor
Financial Company Ltd. approved and declared a quarterly dividend
of US$0.05625 per common share. This
quarterly dividend will be paid on December
13, 2023, to shareholders of record at the close of business
on November 22, 2023. This will be
the sixteenth consecutive dividend payment Sagicor paid to its
shareholders since becoming listing on the Toronto Stock
Exchange.
______________________________________
|
1
|
Represents a non-IFRS
measure. See the Non-IFRS Measures section in this document and in
our MD&A for relevant information about such
measures.
|
ivari Acquisition
On October 3, 2023, Sagicor
announced the completion of its previously announced acquisition of
ivari from Wilton Re Ltd. The purchase price of approximately
US$271 million was funded by a
new US$320 million senior secured term loan facility with
a syndicate of international and Canadian banks. The Company
expects to file a Business Acquisition Report on SEDAR+, including
pro-forma financial statements, on or before December 17,
2023.
Credit Rating Upgrades
On October 5, 2023, Sagicor
announced that S&P Global Ratings ("S&P") and Fitch Ratings
("Fitch") had both upgraded the Company.
S&P upgraded its Issuer Credit Rating (ICR) on the Company
to 'BBB' from 'BB+'. S&P also raised the issue-level rating on
Sagicor's senior unsecured notes to 'BBB' from 'BB+'. As well, the
Group Credit Profile (GCP) was revised upward to 'a-' from 'bbb'.
The outlook is stable.
Fitch upgraded the Issuer Default Rating (IDR) on the Company to
'BBB-' from 'BB'. Fitch also upgraded the senior unsecured debt to
'BB+' from 'BB-'. The rating outlook is stable. In addition, Fitch
has affirmed ivari's Insurer Financial Strength (IFS) rating at
'A-'. The rating outlook is stable.
Normal Course Issuer Bid
Sagicor repurchased 845,400 shares which were cancelled in Q3
2023 for a total cost of approximately US$2.8 million. The number of issued and
outstanding common shares as at September
30, 2023 was 141,984,483.
Management's Discussion and
Analysis and Consolidated Financial Statements
(Unaudited)
This press release, which was approved by the Company's Board of
Directors and Audit Committee, should be read in conjunction with
the Company's unaudited consolidated financial statements and
accompanying MD&A. The unaudited financial statements and
MD&A are available on the Company's website at www.sagicor.com
and will soon be filed on the System for Electronic Document
Analysis and Retrieval Plus ("SEDAR+") at
www.sedarplus.ca.
Conference Call
Sagicor Financial Company Ltd. will host a conference call for
analysts and investors on Tuesday, November 14, 2023, at
1:00 p.m. Eastern Standard Time in
Toronto (2:00 p.m. Atlantic
Standard Time in Barbados and
Trinidad and Tobago, 1:00 p.m. Eastern Standard Time in Jamaica). To listen to the call via live audio
webcast, visit the Company's website at www.sagicor.com, under the
tab "Investor Relations" or at
https://app.webinar.net/n628qnbqD5a. The conference call is
also available by dialing 1-416-764-8688 or 1-888-390-0546 (North
American toll free) or 08006522435 (United Kingdom) or 1-866-290-2216
(Barbados) or 1-800-207-8221
(Trinidad). To join the conference
call without operator assistance, you may register and enter your
phone number at https://emportal.ink/3QqNTwr to receive an
automated call back. A replay will also be available until
December 14, 2023, by dialing
1-416-764-8677 or 1-888-390-0541 (North American toll free),
passcode 225982#. A transcript of the call will also be made
available on www.sagicor.com.
About Sagicor Financial Company
Ltd.
Sagicor Financial Company Ltd. (TSX: SFC) is a leading financial
services provider with over 180 years of history in the
Caribbean, over 90 years of
history in Canada, and a growing
presence in the United States.
Sagicor offers a wide range of products and services, including
life, health, and general insurance, banking, pensions, annuities,
and real estate. Sagicor's registered office is located at
Clarendon House, 2 Church Street, Hamilton, HM 11, Bermuda, with its principal office located at
Cecil F De Caires Building, Wildey, St.
Michael , Barbados.
Additional information about Sagicor can be obtained by visiting
www.sagicor.com.
Forward-Looking
Information
Certain information contained in this news release may be
forward-looking statements. Forward-looking statements are often,
but not always, identified by the use of words such as "expect",
"anticipate", "target", "believe", "foresee", "could", "estimate",
"goal", "intend", "plan", "seek", "will", "may", "would" and
"should" and similar expressions or words suggesting future
outcomes. These forward-looking statements reflect material factors
and expectations and assumptions of Sagicor. Sagicor's estimates,
beliefs, assumptions and expectations contained herein are
inherently subject to uncertainties and contingencies regarding
future events and the impact of both the acquisition of ivari and
the adoption of IFRS 17 on the presentation of Sagicor's financial
statements, and as such, are subject to change. Risks and
uncertainties not presently known to Sagicor or that it presently
believes are not material could cause actual results or events to
differ materially from those expressed in its forward-looking
statements. Additional information on these and other factors that
could affect events and results are included in other documents and
reports that will be filed by Sagicor with applicable securities
regulatory authorities and may be accessed through the SEDAR+
website (www.sedarplus.ca). Readers are cautioned not to place
undue reliance on the financial information or forward-looking
statements contained herein, which reflect Sagicor's estimates,
beliefs, assumptions and expectations (including with respect to
the impact of both the acquisition of ivari and the adoption of
IFRS 17) only as of the date of this document. Sagicor disclaims
any obligation to update or revise any forward-looking statements
contained herein, whether as a result of new information, new
assumptions, future events or otherwise, except as expressly
required by law.
Non-IFRS Measures
The Company reports certain non-IFRS measures and insurance
industry metrics that are used to evaluate its performance. As
non-IFRS measures generally do not have a standardized meaning,
they may not be comparable to similar measures presented by other
companies. Securities regulators require such measures to be
clearly defined and reconciled with their most comparable IFRS
measures. These measures are provided as additional information to
complement IFRS measures by providing further understanding of the
results of the operations of the Company from management's
perspective. Accordingly, these measures should not be considered
in isolation, nor as a substitute for analysis of the Company's
financial information reported under IFRS. Non-IFRS measures used
to analyze the performance of the Company's businesses include but
are not limited to CSM, ROE, book value, MCCSR Ratio, Debt to
Capital Ratio, Total Capital, Core Earnings, and New Business
Production. Please see the "Non-IFRS financial measures" section
below for a reconciliation of these non-IFRS measures.
Contractual service margin (CSM): The CSM represents an
estimate of unearned future profits. This is a new component of
insurance contract liabilities under IFRS 17, which was not
required under IFRS 4. For new business issued under IFRS 4, the
estimated profit or loss over the term of the contract is
recognized in income at the date of issue. Expected future profits
on new business under IFRS 17 are deferred and recorded in the CSM
and amortized into income as insurance services are provided over
the term of the contract. Under IFRS 17, expected losses on new
business are recognized at the date of issue. Net CSM is net of
reinsurance CSM.
Return on Equity (ROE): IFRS does not prescribe the
calculation of return on shareholders' equity and therefore a
comparable measure under IFRS is not available. To determine this
measure, reported net income/(loss) attributable to shareholders is
divided by the total weighted average shareholders' equity for the
period. The quarterly return on shareholders' equity is annualized.
The ROE provides an indication of overall profitability of the
Company.
Book value per share: To determine the book value per share,
shareholders' equity is divided by the number of shares outstanding
at the period end, net of any treasury shares. All components of
this measure are IFRS measures.
Minimum Continuing Capital and Surplus Requirements (MCCSR):
Sagicor voluntarily adopted the Canadian Minimum Continuing Capital
and Surplus Requirement (MCCSR) standard as its risk-based
assessment measure to provide a consolidated view of capital
adequacy. The MCCSR was a standard used by Canadian regulators from
1992 until 2018, when it was superseded by the Life Insurance
Capital Adequacy Test (LICAT, which has also recently been amended
by OSFI). When it was in place, the minimum standard recommended by
the Canadian regulators was an MCCSR of 150.0%. Canadian practices
for calculation of the MCCSR evolved and changed from inception
through its replacement. In jurisdictions where the MCCSR is
currently prescribed, such as Jamaica, the MCCSR guidance is not consistent
with the most recent Canadian MCCSR guidelines or with current
Canadian capital standards under current LICAT. Sagicor has made
certain interpretations in our calculation of the MCCSR, in
consultation with our appointed actuary, which we believe
appropriately reflect the risk-based assessment of our capital
position, including accounting for CSM in MCCSR. As the MCCSR is no
longer prescribed by Canadian regulators and is interpreted in
different ways by our local regulators, there can be no assurance
that Sagicor's MCCSR figures are comparable to current reporting by
Canadian life insurers or that of Canadian life insurers at any
single point in time since the implementation of the MCCSR. IFRS
does not prescribe the calculation for the MCCSR, therefore a
comparable measure under IFRS is not available.
Revenues: Revenues are the sum of three IFRS measures:
insurance revenue, net investment income, and fees and other
income.
Debt to capital ratio: The debt to capital ratio is the ratio
of notes and loans payable (refer to note 11 of the Company's
unaudited consolidated financial statements) to total capital
(excluding participating accounts), where capital is defined as the
sum of notes and loans payable and total equity including total net
CSM and excluding participating accounts. This ratio measures the
proportion of debt a company uses to finance its operations as
compared with its capital.
Total capital: This measure provides an indicator for
evaluating the Company's performance. Total capital ($2.1 billion as at Q3 2023) is the sum of
shareholders' equity ($443 million),
notes and loans payable ($657
million), non-controlling interest ($320 million) and total net CSM
($699 million). This measure is the sum of
several IFRS measures.
New business CSM: This measure is the amount of the
contractual service margin added from contracts initially
recognized in the period.
New Business Production: This measure is equal to the amount
of annuities and life insurance new business paid premium.
Total net CSM: This measure is the balance of the direct
contractual service margin net of reinsurance contractual service
margin.
Net CSM to shareholders: This measure is the amount of the
total net CSM attributable to shareholders.
Shareholders' equity and net CSM to shareholders: This
measure is the sum of total shareholders' equity and net CSM to
shareholders. It is an important measure for monitoring growth and
measuring insurance businesses' value.
In addition, as discussed above, in future quarters, Sagicor
is expected to report core earnings, an estimate of which for Q3
2023 is included above. Core earnings is intended to remove from
reported earnings or loss the impacts of the following items that
create volatility in Sagicor's results under IFRS, or that are not
representative of its underlying operating performance. Each of
these items is classified as a supplementary financial measure and
has no directly comparable IFRS financial measure disclosed in
Sagicor's financial statements to which the measure relates, nor
are reconciliations available, including among others unexpected
market-related impacts, changes in assumptions, management actions,
certain acquisition or disposition related amounts and others such
as one-time costs, amortization of intangibles, and tax effects of
the aforementioned items. The estimated core earnings to
shareholders for Q3 2023 can be reconciled to net income to
shareholders as follows:
Reported Earnings
and Estimated Core Earnings Reconciliation (US$
millions)
|
|
Net income (loss) to
shareholders
|
(3.5)
|
Market experience gains
and losses
|
(2.4)
|
Changes in actuarial
methods and assumptions
|
10.3
|
Other (includes tax
effects, one-time costs, amortization of intangibles)
|
4.6
|
Estimated core
earnings to shareholders
|
9.0
|
SOURCE Sagicor Financial Company Ltd.